Literature DB >> 26903739

Necrotizing scleritis in a case of Vogt-Koyanagi-Harada disease.

Kumar Sambhav1, Parthopratim Dutta Majumder1, Jyotirmay Biswas1.   

Abstract

Entities:  

Year:  2015        PMID: 26903739      PMCID: PMC4738678          DOI: 10.4103/0974-620X.169909

Source DB:  PubMed          Journal:  Oman J Ophthalmol        ISSN: 0974-620X


× No keyword cloud information.
Sir, We examined a 17-year-old female, who presented with complaints of a decrease in vision and metamorphopsia in both the eyes. On examination, her visual acuity was 6/18 in right eye and 6/24 in the left eye. Slit lamp examination showed the presence of keratic precipitates in both the eyes along with anterior chamber cells, flare, and cells in anterior vitreous. On fundus examination, there was presence of small, multiple, yellow choroidal lesions with presence of disc edema and exudative retinal detachment. B-scan confirmed retinal detachment and also showed choroidal thickening. A presumptive diagnosis of Vogt-Koyanagi-Harada syndrome was made. Patient was evaluated with blood investigations which showed raised erythrocytic sedimentation rate and negative venereal disease research laboratory test. Patient was treated with high-dose systemic corticosteroids (1.5 mg/kg) which resulted in complete remission of the disease and patient reached normal visual acuity of 6/6 in both eyes. Patient was on follow-up and was under oral azathioprine and corticosteroid for 18 months. After 27 years, the patient presented with complaints of pain in the left eye, which on examination showed the presence of necrotizing scleritis [Figure 1]. Collagen work up including a rheumatoid factor, ANA, C-ANCA, and P-ANCA were negative. Patient was started on oral azathioprine and prednisolone. The visual acuity in right eye is maintained at 6/6 while left eye had a vision of 3/60 due to the development of chronic macular edema following hypotony. Fundus evaluation revealed sunset glow appearance. The patient is coming for regular follow-up and is improving with treatment.
Figure 1

Slit lamp photograph of left eye showing necrotizing scleritis

Slit lamp photograph of left eye showing necrotizing scleritis Necrotizing scleritis can be associated with systemic connective tissue, including rheumatoid arthritis, Wegener granulomatosis, systemic lupus erythematosus, and sarcoidosis. Patients with scleritis may present either with a known underlying disorder like rheumatoid arthritis, or it can present de novo in the absence of any known systemic illness.[1] There had been reports of the development of Vogt-Koyanagi-Harada in patients of scleritis or concurrent development of bilateral posterior scleritis and Vogt-Koyanagi-Harada disease in a patient.[23] However, in our patient, scleral inflammation was observed following Vogt-Koyanagi-Harada disease and that too after an interval of 27 years. To our knowledge, this is the first report of the development of necrotizing scleritis in a case of Vogt-Koyanagi-Harada disease with a time gap of 27 years.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  3 in total

1.  Early manifestation of vogt-koyanagi-harada disease as unilateral posterior scleritis.

Authors:  Noriko Kouda; Hiroshi Sasaki; Sachiko Harada; Yoshihisa Yamada; Nobuo Takahashi; Kazuyuki Sasaki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

2.  Concurrent bilateral posterior scleritis and Vogt-Koyanagi-Harada disease in a patient with positive rheumatoid factor.

Authors:  K Watanabe; T Kato; S Hayasaka
Journal:  Ophthalmologica       Date:  1997       Impact factor: 3.250

3.  Severity of scleritis and episcleritis.

Authors:  M Sainz de la Maza; N S Jabbur; C S Foster
Journal:  Ophthalmology       Date:  1994-02       Impact factor: 12.079

  3 in total
  1 in total

Review 1.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.